Weigao Blood Purification has passed the IPO review at the Shanghai Stock Exchange, focusing on the two major sectors of hemodialysis and peritoneal dialysis

According to the Zhitong Finance APP, on February 26, Shandong Weigao Blood Purification Products Co., Ltd. (abbreviated as: Weigao Blood Purification) passed the listing committee meeting for its IPO on the Shanghai Stock Exchange main board. The sponsor is Huatai United Securities, and it plans to raise 1.351 billion yuan. China has a large base of end-stage renal disease (ESRD) patients. According to Frost & Sullivan data, in 2022, the number of ESRD patients in China reached 3.8547 million, accounting for 36.7% of the global ESRD patient population; however, the dialysis treatment rate for domestic ESRD patients still has a significant gap compared to most developed countries/regions. The prospectus shows that to better meet the treatment needs of ESRD patients at various stages, Weigao Blood Purification focuses on two major tracks: hemodialysis and peritoneal dialysis, supplemented by the sales of dialysis-related products, making it one of the manufacturers with the richest product lines in blood purification medical products in China. The company's hemodialysis products mainly include hemodialyzers, hemodialysis tubing, and hemodialysis machines, while peritoneal dialysis products mainly include peritoneal dialysis solutions. Since its establishment, Weigao Blood Purification has been focused on the research and development, production, and sales of blood purification medical products. Its main products, hemodialyzers, hemodialysis tubing, hemodialysis machines, and peritoneal dialysis solutions, revolve around the fields of hemodialysis and peritoneal dialysis, supplemented by the sales of dialysis-related products, making it one of the manufacturers with the richest product lines in blood purification medical products in China. The actual funds raised from this issuance, after deducting issuance costs, are planned to be used entirely for the following projects: In terms of finance, for the fiscal years 2021, 2022, 2023, and the first half of 2024, Weigao Blood Purification achieved operating revenues of approximately 2.911 billion yuan, 3.426 billion yuan, 3.532 billion yuan, and 1.626 billion yuan, respectively. During the same period, the company achieved net profits of approximately 260 million yuan, 315 million yuan, 442 million yuan, and 200 million yuan, respectively.